Bengaluru: U.S. medical device maker Boston Scientific said on Monday it has invested $1.5 billion in privately held MiRus LLC in return for a 34% equity stake and potential access to the startup’s heart-valve business. The deal marks Boston Scientific’s re-entry into the market for balloon-expandable transcatheter aortic valve replacement (TAVR) systems, a type of device used to treat certain heart conditions, after it exited the space in May last year citing increased clinical and regulatory requirements.
Boston Scientific said it may acquire MiRus’ TAVR business for additional cash payments totaling $3 billion if certain clinical and regulatory milestones are met. MiRus would also be eligible for additional payments tied to future sales of the device.
TAVR systems are used to treat patients with severe aortic stenosis, a narrowing of the heart’s aortic valve that can restrict blood flow.
MiRus is developing the SIEGEL valve, an experimental device that is not yet approved for commercial sale in any country.
Cardiac devices account for a significant share of Boston Scientific’s revenue, driven by key products such as the Farapulse and Watchman systems.
The agreement also gives Boston Scientific an option to acquire certain MiRus mitral and tricuspid valve assets for an additional payment.
Boston Scientific said the investment is expected to have an immaterial impact on its adjusted earnings per share in 2026.
(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Jonathan Ananda)
